$17.25
+0.14
(+0.82%)▲
1.51%
Downside
Day's Volatility :1.85%
Upside
0.35%
44.75%
Downside
52 Weeks Volatility :48.76%
Upside
7.26%
Period | Electromed Inc | Index (Russel 2000) |
---|---|---|
3 Months | 16.63% | 0.0% |
6 Months | 4.55% | 0.0% |
1 Year | 54.85% | 0.0% |
3 Years | 30.58% | -22.3% |
Market Capitalization | 149.0M |
Book Value | $5.16 |
Earnings Per Share (EPS) | 0.58 |
PE Ratio | 29.74 |
PEG Ratio | 0.0 |
Wall Street Target Price | 26.0 |
Profit Margin | 9.41% |
Operating Margin TTM | 15.74% |
Return On Assets TTM | 8.39% |
Return On Equity TTM | 12.53% |
Revenue TTM | 54.7M |
Revenue Per Share TTM | 6.39 |
Quarterly Revenue Growth YOY | 9.0% |
Gross Profit TTM | 36.5M |
EBITDA | 7.4M |
Diluted Eps TTM | 0.58 |
Quarterly Earnings Growth YOY | 0.81 |
EPS Estimate Current Year | 0.51 |
EPS Estimate Next Year | 0.61 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 50.72%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 31.3M | ↑ 9.07% |
Net Income | 2.0M | ↑ 3.51% |
Net Profit Margin | 6.29% | ↓ 0.34% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 32.5M | ↑ 3.74% |
Net Income | 4.2M | ↑ 111.3% |
Net Profit Margin | 12.81% | ↑ 6.52% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 35.8M | ↑ 10.12% |
Net Income | 2.4M | ↓ 43.23% |
Net Profit Margin | 6.61% | ↓ 6.2% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 41.7M | ↑ 16.51% |
Net Income | 2.3M | ↓ 2.41% |
Net Profit Margin | 5.53% | ↓ 1.08% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 48.1M | ↑ 15.38% |
Net Income | 3.2M | ↑ 37.35% |
Net Profit Margin | 6.59% | ↑ 1.06% |
FY24 | Y/Y Change | |
---|---|---|
Revenue | 54.7M | ↑ 13.83% |
Net Income | 5.2M | ↑ 62.67% |
Net Profit Margin | 9.41% | ↑ 2.82% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 12.1M | ↑ 2.89% |
Net Income | 1.1M | ↑ 10.03% |
Net Profit Margin | 8.91% | ↑ 0.58% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 13.6M | ↑ 12.79% |
Net Income | 1.0M | ↓ 3.91% |
Net Profit Margin | 7.59% | ↓ 1.32% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 12.3M | ↓ 9.46% |
Net Income | 155.0K | ↓ 85.0% |
Net Profit Margin | 1.26% | ↓ 6.33% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 13.7M | ↑ 11.08% |
Net Income | 1.7M | ↑ 980.0% |
Net Profit Margin | 12.23% | ↑ 10.97% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 13.9M | ↑ 1.33% |
Net Income | 1.5M | ↓ 10.81% |
Net Profit Margin | 10.76% | ↓ 1.47% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 14.8M | ↑ 6.93% |
Net Income | 1.8M | ↑ 22.44% |
Net Profit Margin | 12.32% | ↑ 1.56% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 29.4M | ↑ 10.2% |
Total Liabilities | 3.6M | ↓ 23.68% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 33.2M | ↑ 13.25% |
Total Liabilities | 3.0M | ↓ 17.26% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 37.1M | ↑ 11.62% |
Total Liabilities | 4.7M | ↑ 56.68% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 41.4M | ↑ 11.47% |
Total Liabilities | 7.2M | ↑ 53.23% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 45.8M | ↑ 10.74% |
Total Liabilities | 8.1M | ↑ 13.18% |
FY24 | Y/Y Change | |
---|---|---|
Total Assets | 52.9M | ↑ 15.45% |
Total Liabilities | 8.3M | ↑ 2.47% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 42.8M | ↑ 3.5% |
Total Liabilities | 6.4M | ↑ 6.67% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 45.8M | ↑ 6.92% |
Total Liabilities | 8.1M | ↑ 26.24% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 44.1M | ↓ 3.8% |
Total Liabilities | 5.8M | ↓ 28.2% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 47.0M | ↑ 6.58% |
Total Liabilities | 6.6M | ↑ 13.31% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 48.9M | ↑ 4.12% |
Total Liabilities | 6.4M | ↓ 4.0% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 52.9M | ↑ 8.15% |
Total Liabilities | 8.3M | ↑ 31.19% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.6M | ↑ 6.05% |
Investing Cash Flow | -1.4M | ↑ 142.51% |
Financing Cash Flow | -851.2K | ↓ 7367.35% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 4.2M | ↑ 62.03% |
Investing Cash Flow | -977.2K | ↓ 29.53% |
Financing Cash Flow | -548.0K | ↓ 35.61% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 3.1M | ↓ 26.68% |
Investing Cash Flow | -448.0K | ↓ 54.15% |
Financing Cash Flow | -1.2M | ↑ 122.43% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -686.0K | ↓ 122.29% |
Investing Cash Flow | -1.5M | ↑ 240.4% |
Financing Cash Flow | -1.5M | ↑ 25.1% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.3M | ↓ 291.69% |
Investing Cash Flow | -1.7M | ↑ 12.52% |
Financing Cash Flow | -380.0K | ↓ 75.08% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 646.0K | ↓ 52.64% |
Investing Cash Flow | -558.0K | ↑ 21.04% |
Financing Cash Flow | -221.0K | ↓ 2862.5% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 999.0K | ↑ 54.64% |
Investing Cash Flow | -441.0K | ↓ 20.97% |
Financing Cash Flow | 38.0K | ↓ 117.19% |
Sell
Neutral
Buy
Electromed Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Electromed Inc | 15.38% | 4.55% | 54.85% | 30.58% | 176.89% |
![]() Stryker Corporation | 12.3% | 0.36% | 24.19% | 28.8% | 65.26% |
![]() Boston Scientific Corp. | 10.6% | 20.32% | 51.42% | 80.93% | 95.5% |
![]() Edwards Lifesciences Corp. | 9.4% | -28.78% | -12.2% | -45.23% | -7.73% |
![]() Abbott Laboratories | 3.57% | -5.84% | 13.1% | -11.32% | 35.19% |
![]() Medtronic Plc | 10.85% | 5.57% | 12.46% | -33.2% | -16.71% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Electromed Inc | 29.74 | 29.74 | 0.0 | 0.51 | 0.13 | 0.08 | NA | 5.16 |
![]() Stryker Corporation | 39.84 | 39.84 | 2.64 | 12.0 | 0.19 | 0.07 | 0.01 | 51.86 |
![]() Boston Scientific Corp. | 66.34 | 66.34 | 2.01 | 2.41 | 0.09 | 0.05 | NA | 13.85 |
![]() Edwards Lifesciences Corp. | 26.3 | 26.3 | 3.2 | 2.69 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 35.92 | 35.92 | 4.16 | 4.66 | 0.14 | 0.06 | 0.02 | 22.6 |
![]() Medtronic Plc | 30.16 | 30.16 | 1.66 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Electromed Inc | Buy | $149.0M | 176.89% | 29.74 | 9.41% |
![]() Stryker Corporation | Buy | $136.8B | 65.26% | 39.84 | 16.12% |
![]() Boston Scientific Corp. | Buy | $120.2B | 95.5% | 66.34 | 12.0% |
![]() Edwards Lifesciences Corp. | Buy | $40.2B | -7.73% | 26.3 | 23.74% |
![]() Abbott Laboratories | Buy | $198.1B | 35.19% | 35.92 | 13.65% |
![]() Medtronic Plc | Buy | $115.3B | -16.71% | 30.16 | 12.06% |
Insights on Electromed Inc
Revenue is up for the last 4 quarters, 12.32M → 14.83M (in $), with an average increase of 5.9% per quarter
Netprofit is up for the last 2 quarters, 1.49M → 1.82M (in $), with an average increase of 18.3% per quarter
In the last 3 years, Boston Scientific Corp. has given 80.9% return, outperforming this stock by 50.3%
electromed, inc. is a minnesota-based company (nyse mkt: elmd) and the innovative leader in the development, manufacture, and worldwide sales of the smartvest® airway clearance system. the patented system uses high frequency chest wall oscillation (hfcwo), a better-tolerated alternative to chest physiotherapy (cpt), to deliver vigorous, yet comfortable airway clearance treatment for patients battling the consequences of retained secretions. hfcwo has been clinically proven to clear the lungs of excess mucus, improve and reduce lung infections for individuals suffering from various conditions including atelectasis, copd, bronchiectasis, neuromuscular diseases, and cystic fibrosis. electromed, inc. is accredited by the joint commission and is iso 13485:2003 and iso 9001:2008 certified.
Organization | Electromed Inc |
Employees | 174 |
CEO | Mr. Bradley M. Nagel |
Industry | Health Technology |
A Spac I Acquisition Corp
$17.25
+0.82%
Keyarch Acquisition Corp
$17.25
+0.82%
Connexa Sports Technologies Inc
$17.25
+0.82%
Us Value Etf
$17.25
+0.82%
First Wave Biopharma Inc
$17.25
+0.82%
Global X Msci Next Emerging
$17.25
+0.82%
Fat Projects Acquisition Corp
$17.25
+0.82%
Capital Link Global Fintech
$17.25
+0.82%
Applied Uv Inc
$17.25
+0.82%